The prevalence of<unk>  varies depending on the regimen of immunotherapy. The incidence is 0.7 – 1.6% for anti-programmed cell death protein 1 (PD1) agents, 5.7 – 9.1% for anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and about 13.6% for combination therapy. The risk associated with ipilimumab is dose dependent, such that higher doses are associated with higher rates of<unk> . However, other agents (nivolumab and pembrolizumab) are not associated with a dose dependent effect on the risk of immune mediated<unk> . Risk factors for immune mediated<unk>  include Caucasian race, treatment with an anti-CTLA4 based regimen, melanoma as cancer type, nonsteroidal anti-inflammatory drug (NSAID) use, and a prior history of<unk> .
Checkpoint inhibitor induced colitis
Radiation enteropathy
Radiation colitis
Alkylating antineoplastic agent
Lymphocytic colitis
Microscopic colitis
Immunosuppressive drug
NSAID hypersensitivity reactions